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The Haematological Malignancy Research Network (HMRN): a
new information strategy for population based epidemiology
and health service research
Background
Haematological malignancies are common, being the fourth
most frequently diagnosed cancer in both males and females in
the economically developed regions of the world (Ferlay et al,
2004; Jemal et al, 2008; Westlake, 2008). There are over 60
recognized disease subtypes, which differ widely in clinical
presentation, treatment requirements and prognosis (World
Health Organization [WHO], 2008). Key to the delivery and
management of high-quality cancer services for this diverse
patient group is a successful information strategy, with access
to reliable, detailed and relevant data on disease frequency and
outcome (Jensen et al, 1991; National Institute for Clinical
Excellence [NICE], 2003; Department of Health, 2007).
Equally, it is critically important to accurately describe and
understand underlying disease patterns in order to originate
and test hypotheses about pathogenesis (Boyle & Levin, 2008).
Globally, cancer information gathering and dissemination is
sustained by national programmes, such as the Surveillance,
Epidemiology and End Results (SEER) Program in the United
States (US) (http://www.seer.cancer.gov) and the National
Cancer Research Institute (NCRI) in the United Kingdom
(UK) (http://www.ncri.org.uk), as well as international orga-
nizations, such as the WHO International Agency for Research
on Cancer (http://www.iarc). The success of these cancer
information systems should be judged not only by the utility of
their data, but also by the confidence that the end-users have in
the accuracy and analytical methods employed. Whilst meeting
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Summary
The Haematological Malignancy Research Network (HMRN) was established
in 2004 to provide robust generalizable data to inform clinical practice and
research. It comprises an ongoing population-based cohort of patients newly
diagnosed by a single integrated haematopathology laboratory in two
adjacent UK Cancer Networks (population 3Æ6 million). With an emphasis
on primary-source data, prognostic factors, sequential treatment/response
history, and socio-demographic details are recorded to clinical trial
standards. Data on 8131 patients diagnosed over the 4 years 2004–08 are
examined here using the latest World Health Organization classification.
HMRN captures all diagnoses (adult and paediatric) and the diagnostic age
ranged from 4 weeks to 99 years (median 70Æ4 years). In line with published
estimates, first-line clinical trial entry varied widely by disease subtype and
age, falling from 59Æ5% in those aged <15 years to 1Æ9% in those aged over
75 years – underscoring the need for contextual population-based treatment
and response data of the type collected by HMRN. The critical importance of
incorporating molecular and prognostic markers into comparative survival
analyses is illustrated with reference to diffuse-large B-cell lymphoma, acute
myeloid leukaemia and myeloma. With respect to aetiology, several
descriptive factors are highlighted and discussed, including the unexplained
male predominance evident for most subtypes across all ages.
Keywords: diagnostic haematology, epidemiology, leukaemia, lymphoma,
myeloma.
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these exacting requirements is challenging for any cancer, it is
particularly problematic for haematological malignancies
where information gathering and dissemination has long been
acknowledged as a major problem. These concerns were
recently summarized by EUROCARE 4 in their statement that
‘the evolving classification and poor standardization of data
collected on hematological malignancies vitiate the compari-
sons of disease incidence and survival over time and across
regions’(Sant et al, 2009).
A primary requirement of any successful cancer information
strategy is the accurate estimation of disease burden. For
haematological malignancies, two major issues need to be
addressed in order to begin to produce useful data – complete
unbiased ascertainment and accurate capture of detailed
diagnostic data. Traditionally, descriptive information is
reported in the four broad categories shown in Fig 1, which
summarizes data from the UK. This practice stems from the
gradual recognition of clinical entities in the latter half of the
nineteenth century, and originated long before there were any
effective treatments or real understanding of the relationship
between haematological malignancy, the normal bone marrow
and immune system, and before anything was known about
the cellular and genetic basis of malignant transformation.
However, the continued application of such broad categori-
zations severely limits the use of cancer registration data in
epidemiological studies, and the high level of clinical diversity
among the subtypes contained within each of the traditional
groupings means that data presented in this way are of little
value for health service planning and making valid compar-
isons of outcome (NICE, 2003; Sant et al, 2009).
Critically for descriptive epidemiology, the classification of
haematological malignancy has changed markedly over recent
decades, and will continue to do so as innovative diagnostic
methods and techniques are developed (WHO, 2001, 2008).
Fig 1. Cancer registrations United Kingdom, 2005.
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In 2001 the WHO produced, for the first time, a consensus
classification that defined disease entities in terms of immu-
nophenotype, genetic abnormalities and clinical features.
However, although this classification was adopted into clinical
practice almost uniformly around the world, it did not have an
immediate effect on cancer registration practice, where lack of
consistency in the depth and detail of pathological diagnosis
means that population-based data continues to be reported in
broad disease categories (Ferlay et al, 2004; Verdecchia et al,
2007; Jemal et al, 2008; Westlake, 2008; National Cancer
Intelligence Network, 2009a; Rachet et al, 2009). This is largely
a reflection of the fact that unlike many other cancers,
haematological neoplasms are diagnosed using multiple
parameters including a combination of histology, cytology,
immunophenotyping, cytogenetics, imaging and clinical data.
This range and depth of data is difficult for cancer registries to
access systematically, forming a barrier both to the complete
ascertainment and to the collection of diagnostic data at the
level of detail required to implement the latest WHO
classification (WHO, 2001, 2008). Furthermore, in practice,
even within some of the best defined WHO categories there is a
need to qualify the final diagnosis even further using additional
clinical and biological prognostic factors before valid outcome
comparisons can be made (The International Non-Hodgkin’s
Lymphoma Prognostic Factors Project, 1993; Hasenclever &
Diehl, 1998; Vasconcelos et al, 2003; Weltermann et al, 2004;
Buske et al, 2006; Sehn et al, 2007; Dicker et al, 2009).
The diagnostic complexity of haematological malignancies is
mirrored by the wide diversity of treatment pathways. This
diversity includes not only the intensity of treatment, but also
its purpose and its duration. Whilst most cancer treatment can
be categorized as potentially curative or palliative, there are
increasing numbers of patients being diagnosed with more
indolent forms of haematological malignancy whose life
expectancy has been improved through increasingly effective
therapy delivered continuously or episodically over a pro-
tracted period of time (National Institute for Clinical Excel-
lence, 2003; O’Brien et al, 2003; Weber et al, 2007). Indeed, for
many conditions, such as chronic myeloid leukaemia (CML),
the prevalence of patients on active treatment is now many
times greater than the annual incidence; and these treatment
developments are having a major impact on the health
economy (Department of Health, 2007). Longitudinal data of
the type required to inform these changes are not routinely
collected, but are clearly of critical importance for planning
future haemato-oncology services, as well as for modelling the
impact of new treatment approaches.
In response to the challenges outlined above, the Haema-
tological Malignancy Research Network (HMRN) was estab-
lished in the UK in 2004 (http://www.hmrn.org). HMRN was
devised with the overarching aim of overcoming existing
limitations and producing high quality functional data
through the development of an innovative population-based
registry. This unique venture combines the expertise of a single
integrated haematopathology laboratory, an active clinical
network, and data collection/analysis conducted by a specialist
epidemiology unit. This paper describes the infrastructure of
HMRN and discusses the use of the data, demonstrating its
potential to support epidemiological research as well as health
service planning and management.
Methods
In the UK, cancer care is co-ordinated through a series of 37
area-based Cancer Networks, each covering a population
between 700 000 and 3 million people. Cancer Networks are
responsible for bringing together health service commissioners
and providers, the voluntary sector and local authorities to
deliver high quality care within the UK National Health Service
(NHS). HMRN collects detailed information about all haema-
tological malignancies diagnosed in two adjacent UK Cancer
Networks; these are the Yorkshire Cancer Network and the
Humber & Yorkshire Coast Cancer Network (total population
3Æ6 million).
Within the HMRN region, patient care is provided by a
unified clinical network operating across 14 hospitals orga-
nized within five adult multi-disciplinary teams (MDTs) and a
network-wide paediatric oncology service. As a matter of
policy, all haematological malignancy diagnoses within the
region (whether originating from the NHS or private sources
and irrespective of assumed prognosis and treatment intent)
are made at a single specialist haematopathology laboratory –
the Haematological Malignancy Diagnostic Service (http://
www.HMDS.org) – and it is from here that all HMRN patients
are ascertained. HMDS, which was cited in the 2007 UK
Department of Health Cancer Reform Strategy as ‘the model
for delivery of complex diagnostic services’(Department of
Health, 2007), provides a fully integrated diagnostic pathway
in a single department, bringing together the relevant
technology and expertise (including histology, cytology,
immunophenotyping and molecular cytogenetics) required
for the diagnosis and on-going monitoring of all haematolog-
ical malignancies. A sophisticated custom-designed web data-
base is used to handle clinical diagnoses, specimen tracking
and reporting; all diagnoses, including disease transformations
and progressions, are automatically coded to International
Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)
(WHO, 2000).
Network clinical teams work to common guidelines cover-
ing investigation, treatment and follow-up. Following diagno-
sis a core clinical dataset is extracted for all patients from
medical records at each of the 14 HMRN hospitals. Whilst the
vast majority of patients are treated within haematology,
records are traced across the various other disciplines and
hospitals involved in patient care in order to reflect the totality
of the pathway. The information collected includes demo-
graphic details, prognostic factors including imaging, and a full
sequential treatment history with response and outcome
recorded for all episodes. These data are acquired by a process
of active collection by expert HMRN dedicated research staff,
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working to agreed operating procedures and data standards,
with strict and continuous cross-validation within a transpar-
ent peer review process. A critically important feature of data
acquisition is the emphasis on primary source information;
and whilst details of disease stage at diagnosis are recorded if
documented in the medical records, primary data from
radiology reports, blood tests, clinical examination, and
clinician summaries are also recorded, enabling embedded
algorithms to automatically generate stage and prognostic
scores. All details are abstracted onto structured forms (each
malignancy having its own specially adapted version) and
entered onto the web-based system, which integrates HMRN
and HMDS data. Full details of the HMRN and copies of data
abstraction forms are shown on our website (http://
www.hmrn.org).
HMRN has full ethical approval and Section 60 exemption
(now Section 251) to collect data for audit and research on
haematological malignancy patients diagnosed within the
region. For the purposes of the present analysis, population
data were obtained for the HMRN region and for the UK as a
whole from the 2001 census (Office for National Statistics,
2001). Incidence rates and corresponding 95% confidence
intervals (CIs) were estimated using Poisson regression and
survival curves by the Kaplan–Meier method. All analyses were
conducted using the Stata 10 statistical software (Stata-
Corp LP, College Station, TX, USA).
Results
Descriptive findings are presented here for 8131 patients newly
diagnosed with a haematological neoplasm between 1 Sep-
tember 2004 and 31 August 2008 in the HMRN region. Of
these, 224 (2Æ8%) patients had a second haematological
neoplasm diagnosed during the 4-year period either because
of disease progression or transformation, or because of a
concurrent diagnosis with a different cell lineage, yielding 8355
diagnoses in total. These 8355 diagnoses are distributed
according to the WHO 2001 classification (WHO, 2001) in
Table I. Twenty-three main groupings are shown in bold, and
contributory subtypes with five or more diagnoses are also
listed. In addition to frequency, information on sex (% male),
age at diagnosis (median) and first line clinical trial recruit-
ment (% of total) are also presented.
Whist a haematological malignancy can occur at any age, as
with most other cancers, the likelihood of diagnosis increased
markedly with increasing age (Fig 2). The median age at
diagnosis within HMRN over the 4 years 2004–08 was
70Æ4 years for all haematological neoplasms combined, with a
range of 4 weeks to 99 years. Age-specific male rates were
generally higher than female rates (lines in Fig 2), the
divergence between the two becoming progressively more
marked over the age of 50 years. There was clearly a
pronounced male excess across the majority of myeloid and
lymphoid subtypes, but despite this, more women than men
were diagnosed over the age of 80 years (bars in Fig 2). This
apparent discrepancy arose because more women than men
survive to reach old age, as can be seen from Fig 3 which shows
the age and sex structure of HMRN’s population (bars) as well
as that of the UK as a whole (lines).
With a combined population of 3Æ6 million it is, perhaps,
not surprising that HMRN’s regional structure mirrored that
of the UK as a whole in terms of age and sex (Fig 3). Average
annual incidence rates for the 23 main groups and expected
annual frequencies for the UK as a whole, estimated by
applying HMRN sex- and age- (5-year age strata) specific rates
to equivalent UK sex- and age-specific population strata, are
presented in Table II. A direct comparison with published
figures could not be made as national cancer registrations are
not coded to ICD-O-3, and not all of the categories shown in
Table II were uniformly compiled (myeloproliferative neo-
plasms and myelodysplastic syndromes, for example). This is
one of the reasons why, for both males and females, the overall
estimated levels based on HMRN rates are almost 50% higher
than the 2005 UK cancer registration frequencies presented in
Fig 1. More detailed downloadable user-defined breakdowns
by subtype, age and sex can be obtained from our website
(http://www.hmrn.org).
The sex-specific incidence rate ratios (male rate/female rate)
together with their standard errors are shown separately for
myeloid and lymphoid subtypes with 10 or more diagnoses in
Fig 4, which is ordered according to the magnitude of the rate
ratio. As might be expected, some related conditions had
similar sex rate ratios, that of monoclonal gammopathy of
undetermined significance (MGUS) and myeloma, for exam-
ple, being identical (1Æ4; 95% CI, 1Æ2–1Æ6). Whereas for others,
such as chronic lymphocytic leukaemia (CLL, 1Æ7; 95% CI, 1Æ5–
2Æ0) and monoclonal B-cell lymphocytosis (MBL, 1Æ2; 95% CI,
1Æ0–1Æ5) there were differences. Variations were also evident
within some of the main diagnostic categories. For acute
myeloid leukaemia (AML), for example, the overall rate ratio
was 1Æ1, but this ranged from 0Æ7 for therapy-related AML to
1Æ9 for AML with core binding factor. Likewise T-cell
lymphomas, with an overall rate ratio of 1Æ4, ranged from
for 0Æ5 for angioimmunoblastic T-cell lymphoma to 2Æ1 for
anaplastic large cell lymphoma of T/null type.
Box and whisker summary age plots broadly arranged
according to the magnitude of the median ages given in the
third column of Table I are shown separately for myeloid and
lymphoid subtypes with 10 or more diagnoses in Fig 5. Among
myeloid neoplasms, AML spanned the entire age range.
However, this concealed distinct patterns associated with
genetically defined subtypes. For example, the median age of
patients with 11q23 rearrangements was 17Æ9 years, demon-
strating that this largely paediatric malignancy nevertheless
occurs sporadically up to the age of 50 years. At the other end
of the age spectrum, therapy-related AML had a median age of
71 years and was not recorded in the present series of HMRN
patients before the age of 55 years. A strong relationship
between age and subtype was also evident among lymphoid
neoplasms, the median age at diagnosis ranging from
A. Smith et al
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Table I. Diagnostic characteristics: Haematological Malignancy Research Network (HMRN), 2004–2008.
Neoplasm (ICD–O3) Total
Males
(%)
Median age
at diagnosis
(years)
First Line
treatment trial
entry (%)
All diagnoses 8355 54Æ9 70Æ4 7Æ2
Chronic myeloid leukaemia (9875/3) 137 61Æ3 59Æ1 11Æ0
Myeloproliferative neoplasms 822 41Æ5 71Æ4 0Æ2
Chronic myeloproliferative neoplasm (9960/3) 750 40Æ1 71Æ2 0Æ3
Chronic myeloproliferative neoplasm with myelofibrosis (9961/3) 55 61Æ8 73Æ9 –
Hypereosinophilic syndrome (9964/3) 9 44Æ4 55Æ5 –
Systemic mastocytosis (9741/3) 8 25Æ0 62Æ5 –
Chronic myelomonocytic leukaemia (9945/3) 76 63Æ2 75Æ6 –
Myelodysplastic syndromes 509 69Æ0 75Æ9 4Æ7
Refractory anaemia with ringed sideroblasts (9982/3) 96 62Æ5 77Æ4 –
Refractory anaemia with excess blasts (9983/3) 220 68Æ2 75Æ1 9Æ5
Refractory cytopenia with multilineage dysplasia (9985/3) 193 73Æ1 75Æ9 –
Acute myeloid leukaemia (AML) 570 52Æ1 68Æ5 34Æ4
AML not otherwise specified (NOS) (9861/3 9895/3) 462 52Æ6 71Æ4 32Æ3
AML with core binding factors (9871/3 9896/3) 28 64Æ3 42Æ9 53Æ6
AML – probable therapy-related (9920/3) 26 38Æ5 71Æ0 7Æ7
AML with MLL (11q23) rearrangement (9897/3) 10 30Æ0 17Æ9 70Æ0
APML t(15;17)(q22;q11–12) (9866/3) 44 52Æ3 38Æ5 52Æ3
Precursor B-lymphoblastic leukaemia (9836/3) 137 52Æ6 12Æ8 68Æ6
Monoclonal B-cell Lymphocytosis 385 53Æ0 71Æ6 –
Chronic lymphocytic leukaemia (9823/3) 835 62Æ0 71Æ8 0Æ6
Marginal zone lymphoma 390 54Æ4 71Æ9 3Æ1
Systemic marginal zone lymphoma (9699/3) 296 56Æ8 72Æ2 4Æ1
Extranodal marginal zone lymphoma (9699/3) 94 46Æ8 68Æ9 –
Hairy cell leukaemia (9940/3) 48 75Æ0 68Æ0 –
Monoclonal gammopathy of undetermined significance (9765/1) 892 56Æ4 72Æ2 –
Plasma cell myeloma (9732/3) 876 57Æ0 72Æ8 13Æ7
Plasmacytoma (9731/3, 9734/3) 68 64Æ7 68Æ8 13Æ2
Follicular lymphoma (9690/3, 9698/3) 446 46Æ2 64Æ1 3Æ8
Mantle cell lymphoma (9673/3) 100 62Æ0 74Æ3 8Æ0
Diffuse large B-cell lymphoma (9680/3) 1098 52Æ6 70Æ0 4Æ5
Diffuse large B-cell lymphoma (9680/3) 1085 52Æ6 70Æ2 4Æ5
Mediastinal large B-cell lymphoma (9679/3) 13 53Æ8 31Æ7 –
Burkitt lymphoma (9687/3) 54 79Æ6 48Æ2 7Æ4
Lymphoproliferative disorders NOS (9823/3, 9591/3) 263 52Æ9 76Æ8 –
Precursor T-lymphoblastic leukaemia (9837/3) 43 65Æ1 17Æ5 55Æ8
T-cell leukaemia 50 48Æ0 75Æ0 2Æ0
T-cell or natural killer cell large granular lymphocytosis (9831/3) 40 52Æ5 72Æ7 2Æ5
T-cell prolymphocytic leukaemia (9834/3) 10 30Æ0 78Æ3 –
T-cell lymphoma 156 57Æ7 64Æ3 0Æ6
Peripheral T-cell lymphoma – common; unspecified (9702/3) 49 63Æ3 68Æ6 –
Mycosis fungoides (9700/3) 28 71Æ4 64Æ7 –
Primary cutaneous CD30 positive T-cell (9718/3) 23 43Æ5 52Æ3 –
Anaplastic large cell lymphoma of T/null type (9714/3) 18 66Æ7 55Æ6 5Æ6
Angioimmunoblastic T-cell lymphoma (9705/3) 16 31Æ3 74Æ0 –
Enteropathy-type T-cell lymphoma (9717/3) 10 50Æ0 62Æ8 –
Extranodal NK/T-cell lymphoma, nasal type (9719/3) 9 44Æ4 61Æ6 –
Lymphocyte predominant nodular Hodgkin lymphoma (9659/3) 40 72Æ5 43Æ6 –
Classical Hodgkin Lymphoma 360 51Æ1 42Æ1 5Æ8
Nodular sclerosis classical Hodgkin lymphoma (9663/3) 262 48Æ9 37Æ0 5Æ7
Mixed cellularity classical Hodgkin lymphoma (9652/3) 91 54Æ9 60Æ0 5Æ5
Lymphocyte-rich classical Hodgkin lymphoma (9651/3) 7 85Æ7 56Æ6 14Æ3
Descriptive Epidemiology of Haematological Malignancies
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12Æ8 years for precursor B-lymphoblastic leukaemia through to
78Æ3 years for T-cell prolymphocytic leukaemia (Fig 5B). As
well as contrasts, the similarity of the age distributions of
closely related conditions was striking. MBL and CLL, for
example, were adjacent in the plots – the median ages at
diagnosis were 71Æ6 and 71Æ8 years, respectively. Likewise,
MGUS and myeloma had median ages of 72Æ2 and 72Æ8 years,
respectively.
The importance of examining specific disease entities is
further illustrated with reference to AML in Fig 6A, which plots
survival for AML WHO ICD-O-3 categories with 25 or more
patients. In general, prognosis for adults diagnosed with AML
was recognized to be poor, but there was considerable
heterogeneity by subtype with almost three-quarters of those
diagnosed with acute promyelocytic leukaemia t(15;17)(q22;
q11–12) surviving beyond 4 years. In addition to age and
diagnostic category, additional prognostic markers also impact
on survival. This is illustrated further in Fig 6B, which
examines the survival of patients diagnosed with AML not
otherwise specified (NOS) according to the mutation status of
the tyrosine kinase receptor FLT3 – those with the mutation
had a significantly poorer survival than those without it
(P = 0Æ006). In the case of B-cell malignancies, clinical indices
based on disease bulk and patient fitness are a well-validated
method of predicting outcome. An example of these prognostic
indicators for B-cell lymphomas is illustrated in Fig 7, which
shows the components of the International Prognostic Index
(IPI) for diffuse large B-cell lymphoma, based on 1043 patients
over 18 years of age who had no prior B-cell disease. The
combinations of cellular and clinical prognostic factors, the
components of which vary according to disease subtype, are
essential for the accurate definition of any given patient
population.
The final column of Table I gives the proportion of patients
entered into a clinical trial as their first line treatment, which
for all haematological malignancies combined was only 7Æ2%,
ranging from 59Æ5% in those under 15 years through to 1Æ9%
in those aged 75 years or more. The highest trial entry was for
precursor B-lymphoblastic leukaemia, reflecting the well
recognized high levels of recruitment for this largely paediatric
cancer. For many other conditions, particularly those that
dominate the older age ranges, recruitment was very low, as
can be seen more clearly in Table III where first line trial entry
proportions are distributed by age at diagnosis and diagnostic
category.
A key determinant of outcome and the health resource
invested is the treatment the patient received throughout the
entire course of their cancer pathway. With the treatment
pathways of haematological malignancies having the potential
to be both multifaceted and protracted, collecting and
presenting these data is particularly challenging. The ability
of our data to reveal this complexity is illustrated in Fig 8
which shows the pathways of two HMRN myeloma patients,
one in a trial and one not in a trial. Following diagnosis, both
patients were constantly monitored within the haematology
department, and had multiple treatment episodes directed
both at disease control and at symptom management. The first
patient, whose disease followed an aggressive course, died
940 d (2Æ6 years) after diagnosis following intensive salvage
treatment with various modalities – radiotherapy as well as
multiple episodes of chemotherapy. The second patient,
however, followed a more indolent course but ultimately still
required multiple lines of treatment and is currently being
treated with lenalidomide 4 years after diagnosis.
Discussion
The Haematological Malignancy Research Network (HMRN)
was established as a resource to support multifaceted popu-
lation-based research and to provide ‘real-time’ information
for monitoring and improving patient care. To achieve these
aims it was necessary to design a system of data collection that
attained a level of detail and completeness that is beyond the
remit of conventional population-based cancer registries. The
success of this programme, as illustrated by the data presented
Fig 2. Age and sex distribution: Haematological Malignancy Research
Network (HMRN), 2004–2008.
Fig 3. Population age and sex structure of the Haematological
Malignancy Research Network (HMRN) region (bars) compared to the
UK as a whole (lines), 2001.
A. Smith et al
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here, depended on the development of a data collection and
analysis pathway that integrated the key diagnostic and clinical
components in a single platform managed by an interdisci-
plinary team with expertise in diagnostics, clinical haemato-
logy and epidemiology.
Epidemiological reports on haematological malignancy
often begin, and sometimes end, by stating that little is known
about the aetiology of the condition(s) under study. The use of
appropriate disease classifications is critical to the research
process; hitherto, however, many studies of haematological
malignancy have been hampered by the need to aggregate their
data into broad groupings, either because primary source
information was recorded in that way or because diagnostic
standards were inconsistently applied (Ferlay et al, 2004;
Westlake, 2008, National Cancer Intelligence Network,
2009a,b; Rachet et al, 2009; Sant et al, 2009). This study is
the first to use the WHO classification (WHO, 2000, 2001,
2008) to examine the age and gender patterns of haematolog-
ical neoplasms in a well defined population, and the benefits of
this are immediately apparent. The analyses revealed that
whilst males are far more likely than females to develop a
haematological neoplasm at any age, there is considerable
variation by subtype (Fig 4), which any aetiological hypothesis
should seek to address. In this regard, exceptions to the
generality of the male excess are also noteworthy – the excess of
women with therapy-related AML, for example, being likely to
reflect the use of chemo/radiotherapy in breast cancer (Martin
et al, 2009).
The relationship between age and some lymphoma and
leukaemia subtypes are also well recognized, and descriptive
information is invariably published separately for children and
adults. This results in data on cancers that are comparatively rare
either in children or in adults often being overlooked – attention
being focussed on the age group where the condition is most
common. Our analysis of haematological neoplasms across the
entire age-range confirmed the fact that sporadic cases of
paediatric-type disease can occur in later life, and vice-versa
(Fig 5). This has clear implications not only for aetiological
hypotheses, but also for the delivery of care to patients with
these conditions. Furthermore, the strong age distribution
Table II. Average annual rates (95% confidence intervals) per 100 000 within the HMRN region 2004–2008, and estimated annual numbers for the
UK as a whole*.
Neoplasm
Total Males Females
Rate (95% CI)
Estimated UK
annual cases
Rate
(95% CI)
Estimated UK
annual cases
Rate
(95% CI)
Estimated UK
annual cases
All diagnoses 58Æ5 (57Æ3–59Æ8) 33 376 66Æ3 (64Æ4–68Æ3) 18 602 51Æ2 (49Æ6–52Æ9) 14 774
Chronic myeloid leukaemia 1Æ0 (0Æ8–1Æ1) 566 1Æ2 (1Æ0–1Æ5) 350 0Æ7 (0Æ5–0Æ9) 216
Myeloproliferative neoplasm 5Æ8 (5Æ4–6Æ2) 3286 4Æ9 (4Æ4–5Æ5) 1391 6Æ6 (6Æ0–7Æ2) 1895
Chronic myelomonocytic leukaemia 0Æ5 (0Æ4–0Æ7) 297 0Æ7 (0Æ5–0Æ9) 192 0Æ4 (0Æ3–0Æ6) 105
Myelodysplastic syndromes 3Æ6 (3Æ3–3Æ9) 2018 5Æ1 (4Æ6–5Æ7) 1417 2Æ2 (1Æ8–2Æ5) 602
Acute myeloid leukaemia 4Æ0 (3Æ7–4Æ3) 2274 4Æ3 (3Æ8–4Æ8) 1202 3Æ7 (3Æ3–4Æ2) 1073
Precursor B-lymphoblastic leukaemia 1Æ0 (0Æ8–1Æ1) 560 1Æ0 (0Æ8–1Æ3) 291 0Æ9 (0Æ7–1Æ1) 269
Monoclonal B-cell lymphocytosis 2Æ7 (2Æ4–3Æ0) 1551 3Æ0 (2Æ6–3Æ4) 835 2Æ5 (2Æ1–2Æ8) 716
Chronic lymphocytic leukaemia 5Æ9 (5Æ5–6Æ3) 3311 7Æ5 (6Æ9–8Æ2) 2094 4Æ3 (3Æ8–4Æ8) 1218
Marginal zone lymphoma 2Æ7 (2Æ5–3Æ0) 1552 3Æ1 (2Æ7–3Æ5) 858 2Æ4 (2Æ1–2Æ8) 695
Hairy cell leukaemia 0Æ3 (0Æ3–0Æ5) 203 0Æ5 (0Æ4–0Æ7) 154 0Æ2 (0Æ1–0Æ3) 49
Monoclonal gammopathy of
uncertain significance
6Æ2 (5Æ8–6Æ7) 3544 7Æ3 (6Æ6–7Æ9) 2023 5Æ3 (4Æ8–5Æ8) 1521
Plasma cell myeloma 6Æ1 (5Æ7–6Æ6) 3459 7Æ2 (6Æ6–7Æ8) 1998 5Æ2 (4Æ6–5Æ7) 1461
Plasmacytoma 0Æ5 (0Æ4–0Æ6) 277 0Æ6 (0Æ5–0Æ9) 180 0Æ3 (0Æ2–0Æ5) 97
Follicular lymphoma 3Æ1 (2Æ8–3Æ4) 1800 3Æ0 (2Æ6–3Æ4) 840 3Æ3 (2Æ9–3Æ7) 960
Mantle cell lymphoma 0Æ7 (0Æ6–0Æ9) 395 0Æ9 (0Æ7–1Æ2) 249 0Æ5 (0Æ4–0Æ7) 146
Diffuse large B-cell lymphoma 7Æ7 (7Æ3–8Æ2) 4371 8Æ3 (7Æ7–9Æ0) 2326 7Æ1 (6Æ5–7Æ7) 2045
Burkitt lymphoma 0Æ4 (0Æ3–0Æ5) 222 0Æ6 (0Æ5–0Æ8) 176 0Æ2 (0Æ1–0Æ3) 46
Lymphoproliferative disorder NOS 1Æ8 (1Æ6–2Æ1) 1025 2Æ0 (1Æ7–2Æ4) 557 1Æ7 (1Æ4–2Æ0) 468
Precursor T-lymphoblastic leukaemia 0Æ3 (0Æ2–0Æ4) 173 0Æ4 (0Æ3–0Æ6) 113 0Æ2 (0Æ1–0Æ3) 60
T-cell leukaemia 0Æ4 (0Æ3–0Æ5) 204 0Æ4 (0Æ2–0Æ5) 100 0Æ4 (0Æ2–0Æ5) 104
T-cell lymphoma 1Æ1 (0Æ9–1Æ3) 639 1Æ3 (1Æ1–1Æ6) 372 0Æ9 (0Æ7–1Æ2) 267
Lymphocyte predominant
nodular Hodgkin
0Æ3 (0Æ2–0Æ4) 185 0Æ4 (0Æ3–0Æ6) 134 0Æ2 (0Æ1–0Æ3) 50
Classical Hodgkin lymphoma 2Æ5 (2Æ3–2Æ8) 1463 2Æ7 (2Æ3–3Æ1) 752 2Æ4 (2Æ1–2Æ8) 711
*Estimated by applying HMRN sex and age (5-year strata) specific rates to equivalent UK strata (Census Dissemination Unit & Office for National
Statistics, 2009).
Not otherwise specified.
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similarities between precursor conditions, such as MBL and
MGUS and their more aggressive counterparts – respectively
CLL and myeloma, provides further evidence that these
conditions are part of a wider continuum (Rawstron et al,
2008; Landgren et al, 2009). Indeed, unlike other cancers,
haematological malignancies are characterized by their ability to
progress and transform, the longitudinal nature of these
processes being capturedbyHMRNdata acquisitionprocedures.
In this, our first report, in-line with current cancer-registration
practice, analyses were based on the number of diagno-
ses (n = 8355) rather than the number of patients (n = 8131).
The proportion of patients with a subsequent diagnosis is
currently small (2Æ8%) – the follow-up period reported on here
being comparatively short and the findings presented being
unaffected by denominator choice. Future analyses on
individual conditions will factor in this complexity and be
based on the number of patients, rather than their diagnoses.
A key observation within our analyses was that the estimated
UK incidence of haematological neoplasms based on HMRN
rates exceeds national registrations by about 50% (Table II).
Whilst this may be partly due to more complete ascertainment
of certain conditions, there are other contributory factors that
could account for this discrepancy. It has been recognized in
recent years, for example, that occult forms of CLL are not
uncommon in the general population, with reports of up to
12% of adults being affected (Rawstron et al, 2007; Nieto et al,
2009). The term MBL is used when the B-cell count in the
peripheral blood is less than 5 · 109/l, and although this
arbitrary cut-off is widely applied, MBL and CLL are part of a
continuum (Rawstron et al, 2008). Hence, the probability that
a patient with MBL or low level CLL will be diagnosed varies
with both local clinical practice and local access to specialist
diagnostic facilities. Many of these patients will neither require
treatment nor have a reduced life expectancy – hence higher
incidence often equates with better survival. Within cancer
registries these patients may not be registered, be registered
inconsistently, or be coded inappropriately. This explains, at
least in part, the large variation in total leukaemia incidence
(A)
(B)
Fig 4. Sex rate ratios: Haematological Malignancy Research Network (HMRN), 2004–2008.
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and survival reported for the Cancer Networks in England
2001–05 (http://www.ncin.org.uk/eatlas) – the incidence
ranged from 13Æ5 per 100 000 in Yorkshire to 7Æ5 per
100 000 in the adjacent Cancer Network (North of England),
with corresponding 1-year survival estimates of 77Æ6% and
64Æ5%, respectively. This is highly unlikely to reflect ‘true’
underlying variation, and almost certainly represents differ-
ences in reporting and ascertainment of the many disease
subtypes that comprise the ‘all leukaemias’ category. Compa-
rable problems exist for MGUS and myeloma, other types of
indolent B-lymphoproliferative disorders, as well as the lower
grade forms of myelodysplasia. In any population within each
of these categories, there will be a pool of undiagnosed
patients, the magnitude of which will vary with local clinical
practice and subsequent data recording.
Whilst individual subtype frequency comparisons between
HMRN and national programmes cannot be made because
their data are not coded to WHO ICD-O-3, it is nonetheless
reassuring to note that HMRN’s rates for clinically evident
disease groupings, such as the Hodgkin lymphomas (Table II),
are very similar to those of NCIN (http://www.ncin.org.uk)
and SEER (http://www.seer.cancer.gov). However, even in
patients with clinically acute disease, where overall levels of
ascertainment are more standard, there are several issues that
must be considered before valid comparisons of clinical
outcome are made between treatment centres. In this regard,
a further crucial step in interpreting findings is the incorpo-
ration of molecular markers. The WHO classification (WHO,
2008), for example, recognizes a number of specific AML
subtypes based on cytogenetic and molecular abnormalities,
each of which has well defined clinical characteristics and
outcomes (Weltermann et al, 2004; Gale et al, 2008; Rau &
Brown, 2009) – the survival plots presented in Fig 6 clearly
show the importance of taking such markers into account.
Patients with more advanced CLL provide another example
where outcome and survival vary with prognostic factors such
as TP53 inactivation and immunoglobulin mutation status
(Vasconcelos et al, 2003; Byrd et al, 2006; Dicker et al, 2009).
Obviously, making comparisons between centres and individ-
uals in the absence of data on prognostic factors could lead to
erroneous conclusions being drawn. This not only has
implications for local governance and research, but also for
the growing number of commercial health care information
providers who routinely tabulate data and rank centres.
(A)
(B)
Fig 5. Age at diagnosis distributions: Haematological Malignancy Research Network (HMRN), 2004–2008.
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The collection of information to a standard comparable to a
clinical trial, in particular the emphasis on primary source
measurements, is integral to HMRN data collection proce-
dures. For example, for diffuse large B-cell lymphoma,
follicular lymphoma and Hodgkin lymphoma, international
prognostic scoring systems are widely used to stratify patients
in clinical trials (Hasenclever & Diehl, 1998; Buske et al, 2006;
Sehn et al, 2007) – it is, however, well recognized that such
indices are not routinely recorded for non-trial patients. As
illustrated in Fig 7, HMRN actively addresses this through the
collection of component data from multiple primary sources,
using disease-specific abstraction forms that enable embedded
algorithms to accurately calculate stage and prognostic score.
In the future, these data will provide the contextual framework
for evaluating clinical outcomes and assessing the generaliz-
ability of clinical trial findings to the wider patient population.
This is a much needed requirement in the UK because, whilst
haemato-oncology has been cited as a specialty with a strong
commitment to clinical trials and evidence based therapy
(National Cancer Research Network, 2009a,b), it is also
recognized that, overall, as few as 5% of patients are treated
in the context of a clinical trial (National Institute for Clinical
Excellence, 2003). In fact, population-based figures on trial
participation are rarely available for haematological malignan-
cies, either as a whole or by subtype, largely because the totality
of the patient population within the relevant disease subtype
groupings is unknown – this is true both in the UK and
elsewhere in the world. Indeed, whether or not a patient is
entered into a clinical trial is affected by many factors, and the
data presented here confirm that this process is far from
random (National Institute for Clinical Excellence, 2003;
Department of Health, 2007). This lack of representativeness
has clear implications for the external validity of trial findings,
as well as for the common tendency to extrapolate trial data for
commissioning purposes (National Institute for Clinical
Excellence, 2003; Murthy et al, 2004; Cronin et al, 2005;
Vickers, 2008; Estey, 2009; Friedberg et al, 2009).
How patients are treated obviously affects outcome, and
here again data for haematological malignancies are particu-
larly variable and complex, as is illustrated in Fig 8, which
shows two examples of HMRN myeloma patient pathways.
This intricacy is captured within HMRN by abstracting
complete treatment histories, which is essential because,
although primary treatment is usually standardized, this is
not so for relapsed patients who may require salvage
therapy(s). In this case potential treatment options and the
allocation to a particular treatment course increasingly depend
on physician and patient choice – as well as national and local
funding policies (Department of Health, 2007, 2008). A similar
situation exists for more indolent conditions, such as CLL and
follicular lymphoma, where the decision to initiate treatment
and subsequent treatment options may vary with both
individual patient and/or clinician choice, as well as with
treatment centre. Importantly, in addition to facilitating
analyses that will enable therapeutic decisions to be based on
evidence of efficacy. The collection of entire treatment histories
also reveals pathways that are amenable to comparative
economic analysis. This will become increasingly relevant as
many patients with haematological malignancies who would
once have died from their disease fairly rapidly, now survive.
However, unlike survivors from other forms of cancer they
often require life-long treatment(s) – either continuously or
episodically. This has major, but poorly defined implications
for the health economy and as such will be a key area for future
HMRN analyses aimed at informing the process of commis-
sioning cancer services.
This review of the first 4 years of HMRN demonstrate that
within the framework of the UK National Health Service
(NHS), it is feasible to collect data to the standard required,
both to inform patient care and to provide the foundation for
current and future research. HMRN was initiated to serve both
research and clinical needs, and as such the capture of all
patients diagnosed and treated is a paramount objective.
Accurately characterizing the case-mix, as we have been able to
do, is critical for interpreting incidence patterns and for
(A)
(B)
Fig 6. Kaplan–Meier survival estimates for (A) AML patients by ICD-
O-3 subtype and (B) for AML not otherwise specified (NOS) patients
according to FLT3 length mutation status: Haematological Malignancy
Research Network (HMRN), 2004–2008.
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interpreting findings from comparative studies of clinical
outcome, but at present, relevant data of this type are rarely
systematically collected (Sehn et al, 2005). HMRN is based in
two Cancer Networks, and as such reflects the infrastructure of
national cancer care delivery in the UK where patients are
diagnosed and treated locally (National Institute for Clinical
Excellence, 2003; National Cancer Intelligence Network,
2009a). The age and sex structure of the population of
3Æ6 million mirrors that of the UK as a whole, and there is no
reason to believe that the population-based findings are not
generalizable to the country as a whole. Furthermore, in
contrast to many other cancers there is little evidence to
suggest that haematological disease varies systematically with
factors such as social class (Smith et al, 2006; National Cancer
Intelligence Network, 2009c), although broad variations with
ethnicity have been reported (National Cancer Intelligence
Network, 2009d). Issues such as these will be investigated in
detail in future reports.
Haematological oncology is changing rapidly, with new
approaches to treatment and diagnosis continually emerging as
diverse patient pathways evolve. There are now examples
where the use of refined diagnostic techniques and classifica-
tions is beginning to uncover underlying genetic factors in the
pathogenesis of haematological neoplasms (Jones et al, 2009;
Kilpivaara et al, 2009). For example, gene expression profiling
and other techniques are now demonstrating the linkage
between disease categories, such as mediastinal B-cell lym-
phoma and classical Hodgkin lymphoma (Rosenwald et al,
2003; Savage et al, 2003), while subdividing others, such as
diffuse large B-cell lymphoma, in ways that may reflect
underlying pathogenesis (Wright et al, 2003; Lossos et al, 2004;
Tome et al, 2005; Malumbres et al, 2008; Alizadeh et al, 2009).
Importantly, HMRN combines the necessary high quality
population-based data collection systems and diagnostic
facilities to further investigate the epidemiology of these
emerging entities.
Fig 7. International Prognostic Index (IPI) derivation from components in diffuse large-B-cell lymphoma (DLBCL): Haematological Malignancy
Research Network (HMRN), 2004–2008. (ECOG, Eastern Cooperative Oncology Group).
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In conclusion, our study demonstrates that it is feasible
to collect haematological malignancy data to the standard
required to inform patient care and provide a solid
foundation for research using the framework of the UK
National Health Service (NHS). Indeed, HMRN’s maturing
data presents an increasingly valuable resource to address
real questions of concern to haematologists, commissioners,
health service researchers and patients. However, the
wide-ranging challenges of acquiring sufficiently detailed
information mean that this model would be extremely
difficult to replicate across the UK as a whole. Accordingly,
a sample method based on stable populations such as
Table III. First-line trial recruitment distributed by age and diagnosis: Haematological Malignancy Research Network (HMRN), 2004–2008.
Overall
Age (years)
0–14 15–29 30–44 45–59 60–74 75+
All Diagnoses Total 8355 158 242 451 1380 3098 3026
Trial (%) 7Æ2 59Æ5 24Æ0 14Æ2 9Æ6 6Æ4 1Æ9
Precursor B-lymphoblastic leukaemia Total 137 73 15 17 13 14 5
Trial (%) 68Æ6 89Æ0 86Æ7 52Æ9 46Æ2 7Æ1 0
Precursor T-lymphoblastic leukaemia Total 43 18 13 3 2 3 4
Trial (%) 55Æ8 83Æ3 61Æ5 0 50Æ0 0 0
Acute myeloid leukaemia Total 570 18 37 53 89 169 204
Trial (%) 34Æ4 61Æ1 73Æ0 64Æ2 55Æ1 34Æ9 7Æ8
Plasma cell myeloma Total 876 – – 14 144 352 366
Trial (%) 13Æ7 – – 35Æ7 21Æ5 16Æ5 7Æ1
Chronic myeloid leukaemia Total 137 – 8 19 46 42 22
Trial (%) 11Æ0 – 0 13Æ3 17Æ4 11Æ9 0
Mantle cell lymphoma Total 100 – – – 11 42 47
Trial (%) 8Æ0 – – – 18Æ2 11Æ9 2Æ1
Burkitt lymphoma Total 54 15 6 5 10 12 6
Trial (%) 7Æ4 0 33Æ3 20 0 0 16Æ7
Classical Hodgkin lymphoma Total 360 16 98 76 53 70 47
Trial (%) 5Æ8 0 7Æ1 5Æ3 7Æ6 5Æ7 4Æ3
Diffuse large B-cell lymphoma Total 1098 9 19 67 206 416 381
Trial (%) 4Æ5 11Æ1 5Æ3 4Æ5 8Æ7 5Æ5 0Æ8
Other haematological malignancies Total 4980 9 46 197 806 1978 1944
Trial (%) 1Æ5 22Æ2 – 3Æ1 1Æ6 2Æ2 0Æ5
Fig 8. Myeloma patient pathway of two patients: Haematological Malignancy Research Network (HMRN), 2004–2008.
A. Smith et al
750 ª 2009 Blackwell Publishing Ltd, British Journal of Haematology, 148, 739–753
HMRN could provide a cost-effective and reliable alternative
to the current information strategy for haematological
cancers.
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Haematological malignancy diagnostic service
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Helen Dickinson, Paul Evans, Andrew Jack, Richard Jones,
Sheila O’Connor, Roger Owen, Andy Rawstron, Steve Rich-
ards, David Swirsky, Reuben Tooze, Lisa Worrillow.
Epidemiology and genetics unit
Pat Ansell, John Blase, Ian Cope, Helen Cox, Simon Crouch,
Will Curson, James Doughty, Jan Farish, Susanne Griffiths,
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